GE HealthCare raises 2026 outlook after strong third quarter

what happened

According to a TradingView report, GE HealthCare published its results for the third quarter ended September 30, 2026. Revenue reached $5.5 billion, up 7.2%, with organic growth of 6.2%. Net income attributable to the company rose to $615 million from $446 million, and adjusted EBIT climbed to $913 million from $761 million. Adjusted EPS came in at $1.34 versus $1.07 a year earlier.

CEO Peter Arduini credited the performance to commercial execution, operational discipline and continued customer demand for new products. For the full year, the company raised its outlook: organic revenue growth of about 4%, adjusted EPS of $4.95 to $5.05, and free cash flow above $1.6 billion. It also agreed to buy SOFIE Biosciences from Trilantic North America for $945 million in cash, with closing expected in the first half of 2027.

Neal Sandy will become president and CEO of Patient Care Solutions on November 16, 2026. The board declared a quarterly dividend of $0.04 per share, 14% higher than the previous quarter.

why it matters

For investors, the key point is that the company raised its forecast rather than merely confirming it, and profit grew faster than revenue. Strong margins and cash flow provide room for the $945 million deal, although total debt stands at $10.0 billion. Guidance changes like this often shape how the wider medical equipment sector is valued.

market impact

GE HealthCare shares: raised guidance and higher margins support the stock

• ▲GE HealthCare shares pressure up — raised full-year guidance and higher adjusted EBIT margin

tags

instruments